
Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Anger as German family business group opens talks with far-right AfD - 2
The 12 biggest space stories of 2025 — according to you - 3
SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests - 4
Israel and Lebanon's Hezbollah continue to trade attacks - 5
Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
Blue Origin launches huge rocket carrying twin NASA spacecraft to Mars
The Iran war’s energy security legacy
Instructions to Really Oversee Unsold SUVs in the Auto Business
Israel strikes south Lebanon after first direct talks in decades
Vaccine exemptions for religious or personal beliefs are rising across the U.S.
Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
6 Modest and Strong Tire Brands
Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
Your kid wants it now. What saying yes, no or not yet teaches kids about money and instant gratification.













